By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem steps up Propofol production as CV-19 response
Bubendorf, Switzerland: –Peptide technology specialist Bachem Group has announced measures and decisions designed to ensure that the global market is kept supplied with the active pharmaceutical ingredient Propofol from its Swiss production site.
Bachem is the world’s leading producer of the anesthetic agent Propofol which it has manufactured for several years at its site in Vionnaz, Switzerland, and is therefore a key supplier to the market.
Moving to 24/7 production
To ensure that the company can reliably continue to satisfy the growing demand for Propofol, which is currently accentuated by the need for additional supplies for the treatment of COVID-19 patients, the team in Vionnaz has expanded production to a 24/7 three-shift operation.
The company is also investing about one million Swiss francs in additional equipment with the aim of guaranteeing its continued supply capability at all times.
Vital supply responsibility
Bachem Group CEO Thomas Meier commented: “As a producer of active pharmaceutical ingredients, we see it as our responsibility to help, reliably and conscientiously, to ensure that patients continue to be supplied with this product even in extraordinary times. With these measures, we are ensuring that the currently required quantities of Propofol can be manufactured and delivered. To ensure that this remains the case in future, we are expanding our production facilities accordingly.”
“Even though Propofol, as a ‘small molecule’, is not part of our core business as such, Bachem will continue to be the market leader in providing a vitally important API for healthcare worldwide – from Switzerland and of first-class quality,” Mr. Meier added.
Leading Partner in Tides
Under its ‘Leading Partner in Tides’ banner, The Bachem Group, is a market leader in the development and manufacture of peptide-based active pharmaceutical ingredients (APIs) as well as a recent entrant in the corresponding market for oligonucleotides, and is also very successful in offering a small range of non-peptidic APIs.
As a full service provider, Bachem offers products for clinical development and commercial applications as well as a comprehensive catalog and exclusive custom synthesis. With 50 years of experience and subsidiaries in Switzerland, the United States, the United Kingdom and Japan, Bachem has become a partner of choice for the biotech and pharma industry worldwide.
The Swiss based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of pepTides, oligonucleoTides and complex organic molecules as active pharmaceutical ingredients (APIs). A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.
With 50 years of experience, headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.
Under its banner Leading Partner in Tides, Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has five production sites in the US, UK and Switzerland along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, and new chemical entities (NCEs) at preclinical, clinical and production scales.
Further information at: www.bachem.com